env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3954-3962

  Fikkert, Valery ^a   Cherepanov, Peter ^a   Van Laethem, Kristel ^a   Hantson, Anke ^a   Van Remoortel, Barbara ^a   Pannecouque, Christophe ^a   De Clercq, Erik ^a   Debyser, Zeger ^a   Vandamme, Anne Mieke ^a   Witvrouw, Myriam ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); AMD 2763; CHEMOKINE RECEPTOR CXCR4; DEXTRAN SULFATE; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; T 134; T 140; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ZIDOVUDINE; ANTIVIRUS AGENT;

AMINO ACID SEQUENCE; ARTICLE; CHIMERIC VIRUS TECHNOLOGY; CROSS RESISTANCE; DIAGNOSTIC TEST; DRUG RESISTANCE; DRUG SENSITIVITY; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ADSORPTION; VIRUS ISOLATION; CELL CULTURE; CHIMERA; DRUG EFFECT; ENVELOPE GENE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL AGENTS; CELLS, CULTURED; CHIMERA; GENES, ENV; GENOTYPE; HIV-1; HUMANS; POLYMERASE CHAIN REACTION;

EID: 0036896463     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3954-3962.2002     Document Type: Article

References (33)

1. Adachi, A. H., E. Gendelman, S. Koenig, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Arakaki, R., H. Tamamura, M. Premanathan, K. Kanbara, S. Ramanan, K. Mochizuki, M. Baba, N. Fujii, and H. Nakashima. 1999. T134, a small molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol. 73:1719-1723.
3. Baba, M., R. Pauwels, J. Balzarini, J. Arnout, J. Desmyter, and E. De Clercq. 1988. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85:6132-6136.
4. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, Y. Iizawa, M. Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa, K. Meguro, and M. Fujino. 1999. A small-molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96:5698-5703.
5. Bridger, G. J., R. T. Skerlj, S. Padmanabhan, S. A. Martellucci, G. W. Henson, M. J. Abrams, N. Yamamoto, K. De Vreese, and R. Pauwels, 1995. Synthesis and structure-activity relationship of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effect of heteroaromatic linkers on the activity of bicyclams. J. Med. Chem. 38:366-378.
6. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
7. Cocchi, F., A. L. DeVico, A. Garzino-Demo, A. Cara, R. C. Gallo, and P. Lusso. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247.
8. De Clercq, E., N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. Thornton, G. Bridger, S. Fricker, G. Henson, M. Abrams, and D. Picker. 1992. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA 89:5286-5290.
9. De Clercq, E., N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, K. De Vreese, Z. Debyser, B. Rosenwirth, P. Peichl, R. Datema, D. Thornton, R. Skerlj, F. Gaul, S. Padmanabhan, G. Bridger, G. Henson, and M. Abrams. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38:668-674.
10. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
11. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, Z. Zhang, W. A. O'Brien, L. Ratner, G. M. Shaw, and E. Hunter. 2001. Sensitivity of human immunodeficiency virus type I to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 gp4l and is consistently modulated by gp120 interactions with the coreceptor, J. Virol. 75:8605-8614.
12. De Vreese, K., V. Kofler-Mongold, C. Leutgeb, V. Weber, K. Vermeire, S. Schacht, J. Anne, E. De Clercq, R. Datema, and G. Werner. 1996. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:689-696.
13. De Vreese, K., D. Reymen, P. Griffin, A. Steinkasserer, G. Werner, G. J. Bridger, J. Este, W. James, G. W. Henson, J. Desmyter, J. Anne, and E. De Clercq. 1996. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antivir. Res. 29:209-219.
14. Esté, J. A., C. Cabrera, J. Blanco, A. Guttierrez, G. Bridger, G. Henson, B. Clotet, D. Schols, and E. De Clercq. 1999. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 73:5577-5585.
15. Esté, J. A., D. Schols, K. De Vreese, K. Van Laethem, A. M. Vandamme, J. Desmyter, and E. De Clercq. 1997. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:98-104.
16. Hertogs, K., M.-P. de Béthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerven, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels, 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiviral drugs. Antimicrob. Agents Chemother. 42:269-276.
17. Horwitz, J. P., J. Chua, and M. Noel. 1964. Nucleoside V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl) thymine. J. Org. Chem. 29:2076-2078.
18. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: A rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
19. Larder, B., D. Richman, and S. Vella. 1998. HIV Resistance and Implications for Therapy. Medicom Inc., Atlanta, Ga.
20. Maschera, B., E. Furfine, and E. D. Blair. 1995. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
21. Miyoshi, I., H. Taguchi, I. Kobonishi, S. Yoshimoto, Y. Ohtsuki, and Y. Shiraishi. 1982. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr. 28:219-228.
22. Murakami, T., T. Nakajima, Y. Koyanagi, K. Tachibana, N. Fujii, H. Tamamura, N. Yoshida, M. Waki, A. Matsumoto, O. Yoshie, T. Kishimoto, N. Yamamoto, and T. Nagasawa. 1997. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:1389-1393.
23. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
24. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
25. Schols, D., S. Struyf, J. Van Damme, J. A. Esté, G. Henson, and E. De Clercq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1383-1388.
26. 7-polyphemusin II). Bioorg. Med. Chem. 6:231-238.
27. Tamamura, H., Y. Xu, T. Hattori, X. Zhang, R. Arakaki, K. Kanbara, A. Omagari, A. Otaka, T. Ibuka, N. Yamamoto, H. Nakashima, and N. Fujii. 1998. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 253:877-882.
28. Vandamme, A.-M., K. Van Laethem, and E. De Clercq. 1999. Managing resistance to anti-HIV drugs. An important consideration for effective disease management. Drugs 57:337-361.
29. Vandamme, A.-M., M. Witvrouw, C. Pannecouque, J. Balzarini, K. Van Laethem, J. C. Schmidt, J. Desmyter, and E. De Clercq. 1999. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs, p. 223-258. In D. Kinchington and R. F. Schinazi (ed.), Methods in Molecular Medicine: Antiviral Methods and Protocols. Humana Press, Totowa, N.J.
30. Vartanian, J. P. 2000. AMD3100 AnorMED. Idrugs 3:811-816.
31. Verrier, F., A. M. Borman, D. Brand, and M. Girard. 1999. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. AIDS Res. Hum. Retrovir. 15:731-743.
32. Witvrouw, M., V. Fikkert, W. Pluymers, B. Matthews, K. Mardel, D. Schols, J. Raff, Z. Debyser, E. De Clercq, G. Holan, and C. Pannecouque. 2000. Polyanionic (i.e. polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol. Pharmacol. 58:1100-1108.
33. Xu, Y., X. Zhang, M. Matsuoka, and T. Hattori. 2000. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 487:185-188